Kaken Pharmaceutical Co., Ltd.
KKPCF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $139 | $18,867 | $18,045 | $24,618 |
| % Growth | -99.3% | 4.6% | -26.7% | – |
| Cost of Goods Sold | $59 | $8,995 | $8,705 | $9,528 |
| Gross Profit | $79 | $9,872 | $9,340 | $15,090 |
| % Margin | 57.1% | 52.3% | 51.8% | 61.3% |
| R&D Expenses | $43 | $5,382 | $8,168 | $4,584 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $35 | $4,474 | $5,289 | $4,662 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2 | $269 | $3 |
| Operating Expenses | $78 | $9,858 | $13,726 | $9,249 |
| Operating Income | $1 | $14 | -$4,386 | $5,841 |
| % Margin | 0.9% | 0.1% | -24.3% | 23.7% |
| Other Income/Exp. Net | $5 | $394 | -$2,200 | $945 |
| Pre-Tax Income | $7 | $408 | -$6,586 | $6,786 |
| Tax Expense | $2 | $137 | -$1,356 | $1,897 |
| Net Income | $5 | $271 | -$5,230 | $4,889 |
| % Margin | 3.5% | 1.4% | -29% | 19.9% |
| EPS | 0.13 | 7.12 | -133.99 | 129.09 |
| % Growth | -98.2% | 105.3% | -203.8% | – |
| EPS Diluted | 0.13 | 7.12 | -133.99 | 129.09 |
| Weighted Avg Shares Out | 38 | 38 | 39 | 38 |
| Weighted Avg Shares Out Dil | 38 | 38 | 39 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $33 | $261 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $6 | -$16 | $639 | $688 |
| EBITDA | $12 | $0 | -$3,750 | $6,532 |
| % Margin | 8.9% | 0% | -20.8% | 26.5% |